ClinicalTrials.gg
CompletedNCT05138016Updated Nov 13, 2026Results posted

Effects of Soft Robotic Exosuit on Exercise Capacity, Biomakers of Neuroplasticity, and Motor Learning After Stroke

An interventional study of Soft exosuit and No Soft exosuit in Stroke, sponsored by Boston University Charles River Campus. Completed at 2 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Boston University Charles River Campus · Not applicable, Interventional, and Basic science

How we know

Updated Nov 13, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
11
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,995 studies in Stroke with a site in United States — 392 open to participants now, 490 under way, 17 of them phase 3. Stroke · United States.

Enrollment
1,330th of 1,621
11 · median 40
Started
2021
with 114 others
No phase
1,124 of 1,995
270 open now
Registered
1,430th of 1,995
by date

Among the 1,995 studies in Stroke with a site in United States, this one is the 1,330th largest by enrollment of the 1,621 interventional ones that give a count, is one of 115 that started in 2021, is one of 1,124 with no phase, and was the 1,430th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

392 of the 1,995 studies in Stroke with a site in United States are open now. Recruiting first, the newest first:

387 more — sign in →

All 392 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,995 studies in Stroke with a site in United States, or all of them as a file.
02

Study summary

High intensity exercise is known to improve a person's ability to learn new motor skills. The goal of this project is to evaluate if a robotic exosuit can help people who have had a stroke perform walking rehabilitation at higher intensities than they are able to without the exosuit. The investigators will measure exercise training intensity, biomarkers of neuroplasticity (e.g., brain-derived neurotrophic factor; BDNF), and motor learning when people poststroke exercise with and without the exosuit. For this protocol, exosuits developed in collaboration with ReWalk™ Robotics will be used.

Aim 1: Determine the effects of a soft robotic exosuit on gait training intensity and serum BDNF in persons post-stroke completing a single bout of high intensity walking.

Hypothesis 1: Exosuits will allow individuals post-stroke to (i) walk at higher intensities or (ii) walk at a high intensity for longer durations.

Hypothesis 2: Training at a higher intensity, or training at high intensity for longer durations, will result in increased serum BDNF.

Aim 2: Determine the effects of a soft robotic exosuit on gait biomechanics measured after a single bout of high intensity walking with versus without a soft robotic exosuit.

Hypothesis 3: A single bout of high intensity walking with an exosuit will lead to demonstrably better gait biomechanics than a single bout of high intensity exercise without an exosuit.

Read the detailed description

Prior studies of the exosuit technology have culminated in strong evidence for the gait-restorative effects of soft robotic exosuits for patients post-stroke by means of substitution for impaired paretic limb function during walking. The present study builds on this work by suggesting that an exosuit's immediate gait-restorative effects can be leveraged during high intensity gait training to produce post-training improvements in gait quality. Indeed, current rehabilitation efforts are focused on either quality or intensity. They focus on gait quality by reducing the training intensity to allow patients to achieve a more normal gait. In contrast, efforts focused on training intensity push participants without regard for the quality of their movements. The investigators posit that exosuits can uniquely enable high intensity gait training that promotes quality of movements.

Acute bouts of high intensity exercise prior to skilled task practice have been shown to enhance motor learning in neurologically intact individuals. However, the impact of high intensity exercise on motor learning in clinical populations remains largely unknown. A major limitation to studying this relationship in survivors of stroke are challenges in achieving and maintaining high intensity exercise levels (>75% max HR) during gait training for durations that are comparable to neurologically intact individuals. Exercising at a lower intensity or for a shorter duration may result in insufficient neurological "priming" for motor learning that typically follows high intensity training-which would be evidenced in reduced production of activity-dependent markers of neuroplasticity (e.g., brain-derived neurotrophic factor; BDNF). For this study, the investigators will use standardized, maximal effort tests to evaluate the ability of a soft robotic exosuit to increase a patient's capacity for high intensity gait training. The investigators will also examine the resulting effect on BDNF and the relationship between training intensity, BDNF and motor learning measures.

03

Conditions studied

  • Stroke

Keywords

  • Neuroplasticity
  • Motor Learning
  • Exercise
  • Soft Robotics
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of stroke
  • Chronic phase of recovery (>6mo post-stroke) (self-report)
  • 18-80 years old (self-report)
  • Independent ambulation (with or without an assistive device) for at least two minutes (confirmed at secondary screening visit)
  • Provide HIPAA Authorization to allow communication with the healthcare provider as needed during the study period
  • Medical clearance by the participant's physician

Exclusion criteria

Exclusion Criteria:

  • Score of > 1 on question 1b and > 0 on question 1c on the NIH Stroke Scale (NIHSS)
  • Inability to communicate
  • Unexplained dizziness in the last 6 months
  • Serious comorbidities that may interfere with the ability to participate in this research (for example: musculoskeletal, cardiovascular, pulmonary, and neurological - other than stroke)
  • Anemia (defined as levels of \<13 g/dL for men and \<12 g/dL for women)
  • Clotting disorders**
  • Have given blood to any other entity within 60 days prior to blood collection
  • History of significant Peripheral Artery Disease (PAD)
  • Unresolved Deep Vein Thrombosis (DVT)
  • Uncontrolled or untreated hypertension
  • Significant paretic ankle contractures (plantarflexion > 5°)
  • Psychiatric or cognitive impairments that may interfere with the proper operation of the device
  • Presence of open wounds or broken skin at device locations requiring medical management
  • Known urethane allergies
  • Pregnancy

    • Note: If the study team suspects neglect or hemianopia at any time during the course of the research, the physical therapist may administer the Star Cancellation Test (https://www.strokengine.ca/en/assess/sct/) for neglect or a visual field test (e.g., showing visual stimuli on different sides of the body) for hemianopia.

      • Note: We may enroll participants who do not have a clotting disorder, but who are on anti-clotting medications.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Exosuit assistance first, then no exosuit

    Participants do progressive cardiovascular exercise testing on a treadmill with soft exosuit assistance. Following a wash out period of 1-2 weeks, progressive cardiovascular exercise testing on a treadmill is done without exosuit assistance.

    Device: Soft exosuit · Behavioral: No Soft exosuit

  • Experimental
    No exosuit, then exosuit assistance

    Participants do progressive cardiovascular exercise testing on a treadmill without exosuit assistance. Following a wash out period of 1-2 weeks, progressive cardiovascular exercise testing on a treadmill is done with exosuit assistance.

    Device: Soft exosuit · Behavioral: No Soft exosuit

Interventions

  • DeviceSoft exosuit

    Progressive cardiovascular exercise testing with soft exosuit assistance, a textile based exosuit that provides mechanical assistance to the paretic plantarflexors and dorsiflexors during walking.

  • BehavioralNo Soft exosuit

    Progressive cardiovascular exercise testing.

06

What researchers measure

Primary outcomes

  1. VO2-Peak

    Average peak oxygen consumption rate.

    Time frame: Last 30 seconds of maximal effort exercise test.

  2. Duration of High Intensity Exercise

    Minutes spent exercising at greater than or equal to 76% age-predicted heart rate maximum value.

    Time frame: From the beginning to the end of the test, as determined based on standardized test termination criteria (e.g., volitional fatigue, cardiovascular abnormalities, or physical safety)

  3. Concentration of Brain-derived Neurotrophic Factor (BDNF)

    A neurotrophic factor that is essential for learning and memory.

    Time frame: Baseline.

  4. Concentration of Brain-derived Neurotrophic Factor (BDNF)

    A neurotrophic factor that is essential for learning and memory.

    Time frame: Immediately after maximal effort exercise test.

  5. Propulsion Symmetry

    Propulsion symmetry was computed as the paretic-limb peak propulsion divided by the sum of paretic- and non-paretic-limb peak propulsion, with peaks taken from the mass-normalized anterior ground reaction force of each limb. Values approaching 50% indicate greater interlimb symmetry. This measure was used to evaluate training-induced changes in gait symmetry within each condition.

    Time frame: Baseline.

  6. Propulsion Symmetry

    Propulsion symmetry was computed as the paretic-limb peak propulsion divided by the sum of paretic- and non-paretic-limb peak propulsion, with peaks taken from the mass-normalized anterior ground reaction force of each limb. Values approaching 50% indicate greater interlimb symmetry. This measure was used to evaluate training-induced changes in gait symmetry within each condition.

    Time frame: Immediately after maximal effort exercise test.

07

Results

Posted Nov 13, 2026

Participant flow

First exercise period (Day 1)
Participant flow — First exercise period (Day 1)
MilestoneNo-Exosuit Then ExosuitExosuit Then No-Exosuit
Started47
Completed47
Not completed00
Washout period (1-2 weeks)
Participant flow — Washout period (1-2 weeks)
MilestoneNo-Exosuit Then ExosuitExosuit Then No-Exosuit
Started47
Completed47
Not completed00
Second exercise period (Day 2)
Participant flow — Second exercise period (Day 2)
MilestoneNo-Exosuit Then ExosuitExosuit Then No-Exosuit
Started47
Completed47
Not completed00

Outcome measures

PrimaryVO2-Peak

Average peak oxygen consumption rate.

Time frame:
Last 30 seconds of maximal effort exercise test.
Reported as:
Mean · ml O2/kg/min
VO2-Peak
ml O2/kg/minExosuitNo Exosuit
VO2-Peak18.83 ± 1.6517.08 ± 1.50
PrimaryDuration of High Intensity Exercise

Minutes spent exercising at greater than or equal to 76% age-predicted heart rate maximum value.

Time frame:
From the beginning to the end of the test, as determined based on standardized test termination criteria (e.g., volitional fatigue, cardiovascular abnormalities, or physical safety)
Reported as:
Mean · Minutes
Duration of High Intensity Exercise
MinutesExosuitNo Exosuit
Duration of High Intensity Exercise12.45 ± 1.4110.39 ± 1.36
PrimaryConcentration of Brain-derived Neurotrophic Factor (BDNF)

A neurotrophic factor that is essential for learning and memory.

Time frame:
Baseline.
Reported as:
Mean · ng/ml
Concentration of Brain-derived Neurotrophic Factor (BDNF)
ng/mlExosuitNo Exosuit
Concentration of Brain-derived Neurotrophic Factor (BDNF)40.96 ± 3.2845.15 ± 3.78
PrimaryConcentration of Brain-derived Neurotrophic Factor (BDNF)

A neurotrophic factor that is essential for learning and memory.

Time frame:
Immediately after maximal effort exercise test.
Reported as:
Mean · ng/ml
Concentration of Brain-derived Neurotrophic Factor (BDNF)
ng/mlExosuitNo Exosuit
Concentration of Brain-derived Neurotrophic Factor (BDNF)46.92 ± 3.9648.49 ± 3.67
PrimaryPropulsion Symmetry

Propulsion symmetry was computed as the paretic-limb peak propulsion divided by the sum of paretic- and non-paretic-limb peak propulsion, with peaks taken from the mass-normalized anterior ground reaction force of each limb. Values approaching 50% indicate greater interlimb symmetry. This measure was used to evaluate training-induced changes in gait symmetry within each condition.

Time frame:
Baseline.
Reported as:
Mean · Percentage
Propulsion Symmetry
PercentageExosuitNo Exosuit
Propulsion Symmetry31 ± 235 ± 2
PrimaryPropulsion Symmetry

Propulsion symmetry was computed as the paretic-limb peak propulsion divided by the sum of paretic- and non-paretic-limb peak propulsion, with peaks taken from the mass-normalized anterior ground reaction force of each limb. Values approaching 50% indicate greater interlimb symmetry. This measure was used to evaluate training-induced changes in gait symmetry within each condition.

Time frame:
Immediately after maximal effort exercise test.
Reported as:
Mean · Percentage
Propulsion Symmetry
PercentageExosuitNo Exosuit
Propulsion Symmetry30 ± 333 ± 2

Adverse events

Collected over From Day 1 to Day 2, separated by a washout period of 1-2 weeks, with a total of up to 3 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Exosuit0/11 (0%)0/11 (0%)0/11 (0%)
No Exosuit0/11 (0%)0/11 (0%)1/11 (9.1%)
Most frequent other events
Most frequent other events
EventExosuitNo Exosuit
A decrease in heart rate and abnormal blood pressure.General disorders0/111/11

Baseline characteristics

Age, Continuous
Age, Continuous(years)No-Exosuit Then ExosuitExosuit Then No-ExosuitTotal
Mean55 ± 1659 ± 1258 ± 13
Sex: Female, Male
Sex: Female, Male(Participants)No-Exosuit Then ExosuitExosuit Then No-ExosuitTotal
Female123
Male358
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)No-Exosuit Then ExosuitExosuit Then No-ExosuitTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)No-Exosuit Then ExosuitExosuit Then No-ExosuitTotal
United States4711
08

Study locations

2 sites
  • Boston University
    Boston, Massachusetts 02215, United States
  • Spaulding Rehabiliation Hospital
    Charlestown, Massachusetts 02129, United States
09

References and documents

Publications

  • Awad LN, Bae J, Kudzia P, Long A, Hendron K, Holt KG, O'Donnell K, Ellis TD, Walsh CJ. Reducing Circumduction and Hip Hiking During Hemiparetic Walking Through Targeted Assistance of the Paretic Limb Using a Soft Robotic Exosuit. Am J Phys Med Rehabil. 2017 Oct;96(10 Suppl 1):S157-S164. doi: 10.1097/PHM.0000000000000800. PubMed 28777105 ↗
  • Awad LN, Bae J, O'Donnell K, De Rossi SMM, Hendron K, Sloot LH, Kudzia P, Allen S, Holt KG, Ellis TD, Walsh CJ. A soft robotic exosuit improves walking in patients after stroke. Sci Transl Med. 2017 Jul 26;9(400):eaai9084. doi: 10.1126/scitranslmed.aai9084. PubMed 28747517 ↗
  • Awad LN, Kudzia P, Revi DA, Ellis TD, Walsh CJ. Walking faster and farther with a soft robotic exosuit: Implications for post-stroke gait assistance and rehabilitation. IEEE Open J Eng Med Biol. 2020;1:108-115. doi: 10.1109/ojemb.2020.2984429. Epub 2020 Apr 2. PubMed 33748765 ↗
  • Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci. 2015 Dec 10;11(6):1164-78. doi: 10.5114/aoms.2015.56342. Epub 2015 Dec 11. PubMed 26788077 ↗
  • Charalambous CC, Helm EE, Lau KA, Morton SM, Reisman DS. The feasibility of an acute high-intensity exercise bout to promote locomotor learning after stroke. Top Stroke Rehabil. 2018 Mar;25(2):83-89. doi: 10.1080/10749357.2017.1399527. Epub 2017 Nov 5. PubMed 29105605 ↗
  • Crozier J, Roig M, Eng JJ, MacKay-Lyons M, Fung J, Ploughman M, Bailey DM, Sweet SN, Giacomantonio N, Thiel A, Trivino M, Tang A. High-Intensity Interval Training After Stroke: An Opportunity to Promote Functional Recovery, Cardiovascular Health, and Neuroplasticity. Neurorehabil Neural Repair. 2018 Jun;32(6-7):543-556. doi: 10.1177/1545968318766663. Epub 2018 Apr 20. PubMed 29676956 ↗
  • Dinoff A, Herrmann N, Swardfager W, Lanctot KL. The effect of acute exercise on blood concentrations of brain-derived neurotrophic factor in healthy adults: a meta-analysis. Eur J Neurosci. 2017 Jul;46(1):1635-1646. doi: 10.1111/ejn.13603. Epub 2017 Jun 19. PubMed 28493624 ↗
  • Ferris LT, Williams JS, Shen CL. The effect of acute exercise on serum brain-derived neurotrophic factor levels and cognitive function. Med Sci Sports Exerc. 2007 Apr;39(4):728-34. doi: 10.1249/mss.0b013e31802f04c7. PubMed 17414812 ↗
  • Fletcher GF, Ades PA, Kligfield P, Arena R, Balady GJ, Bittner VA, Coke LA, Fleg JL, Forman DE, Gerber TC, Gulati M, Madan K, Rhodes J, Thompson PD, Williams MA; American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee of the Council on Clinical Cardiology, Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular and Stroke Nursing, and Council on Epidemiology and Prevention. Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation. 2013 Aug 20;128(8):873-934. doi: 10.1161/CIR.0b013e31829b5b44. Epub 2013 Jul 22. No abstract available. PubMed 23877260 ↗
  • Leech KA, Hornby TG. High-Intensity Locomotor Exercise Increases Brain-Derived Neurotrophic Factor in Individuals with Incomplete Spinal Cord Injury. J Neurotrauma. 2017 Mar 15;34(6):1240-1248. doi: 10.1089/neu.2016.4532. Epub 2017 Jan 18. PubMed 27526567 ↗
  • Mackay CP, Kuys SS, Brauer SG. The Effect of Aerobic Exercise on Brain-Derived Neurotrophic Factor in People with Neurological Disorders: A Systematic Review and Meta-Analysis. Neural Plast. 2017;2017:4716197. doi: 10.1155/2017/4716197. Epub 2017 Sep 19. PubMed 29057125 ↗
  • Nepveu JF, Thiel A, Tang A, Fung J, Lundbye-Jensen J, Boyd LA, Roig M. A Single Bout of High-Intensity Interval Training Improves Motor Skill Retention in Individuals With Stroke. Neurorehabil Neural Repair. 2017 Aug;31(8):726-735. doi: 10.1177/1545968317718269. Epub 2017 Jul 8. PubMed 28691645 ↗
  • Roig M, Skriver K, Lundbye-Jensen J, Kiens B, Nielsen JB. A single bout of exercise improves motor memory. PLoS One. 2012;7(9):e44594. doi: 10.1371/journal.pone.0044594. Epub 2012 Sep 4. PubMed 22973462 ↗
  • Skriver K, Roig M, Lundbye-Jensen J, Pingel J, Helge JW, Kiens B, Nielsen JB. Acute exercise improves motor memory: exploring potential biomarkers. Neurobiol Learn Mem. 2014 Dec;116:46-58. doi: 10.1016/j.nlm.2014.08.004. Epub 2014 Aug 14. PubMed 25128877 ↗
  • Snow NJ, Mang CS, Roig M, McDonnell MN, Campbell KL, Boyd LA. The Effect of an Acute Bout of Moderate-Intensity Aerobic Exercise on Motor Learning of a Continuous Tracking Task. PLoS One. 2016 Feb 22;11(2):e0150039. doi: 10.1371/journal.pone.0150039. eCollection 2016. PubMed 26901664 ↗
  • Statton MA, Encarnacion M, Celnik P, Bastian AJ. A Single Bout of Moderate Aerobic Exercise Improves Motor Skill Acquisition. PLoS One. 2015 Oct 27;10(10):e0141393. doi: 10.1371/journal.pone.0141393. eCollection 2015. PubMed 26506413 ↗
  • Vaynman S, Ying Z, Gomez-Pinilla F. Hippocampal BDNF mediates the efficacy of exercise on synaptic plasticity and cognition. Eur J Neurosci. 2004 Nov;20(10):2580-90. doi: 10.1111/j.1460-9568.2004.03720.x. PubMed 15548201 ↗
  • Voss MW, Vivar C, Kramer AF, van Praag H. Bridging animal and human models of exercise-induced brain plasticity. Trends Cogn Sci. 2013 Oct;17(10):525-44. doi: 10.1016/j.tics.2013.08.001. Epub 2013 Sep 9. PubMed 24029446 ↗
  • Warraich Z, Kleim JA. Neural plasticity: the biological substrate for neurorehabilitation. PM R. 2010 Dec;2(12 Suppl 2):S208-19. doi: 10.1016/j.pmrj.2010.10.016. PubMed 21172683 ↗
  • Neeper SA, Gomez-Pinilla F, Choi J, Cotman C. Exercise and brain neurotrophins. Nature. 1995 Jan 12;373(6510):109. doi: 10.1038/373109a0. No abstract available. PubMed 7816089 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Aug 2022, 13 months.

Results were first posted in Nov 2026, 4 years 2 months after primary completion.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's 13 months is below that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2021
First posted
Nov 30, 2021
StartActual
Jul 21, 2021
Primary completionActual
Aug 28, 2022
CompletionActual
Jan 17, 2023
Results first posted
Nov 13, 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 13, 2026
Interventions
Arms added: Exosuit assistance first, then no exosuit·No exosuit, then exosuit assistance; arms removed: Exercise testing with soft exosuit assistance·Exercise testing without soft exosuit assistance
Nov 13, 2026
Primary outcomes
5 edited
What changed in the outcomes
  • EditedDuration of high intensity exerciseHigh Intensity ExerciseTime frame: From the beginning to the end of the test, as determined based on standardized test termination criteria (e.g., volitional fatigue, cardiovascular abnormalities, or physical safety)
  • EditedConcentration of brainBrain-derived neurotrophic factorNeurotrophic Factor (BDNF)Time frame: Baseline.
  • EditedConcentration of brainBrain-derived neurotrophic factorNeurotrophic Factor (BDNF)Time frame: Immediately after maximal effort exercise test.
  • EditedForward PropulsionPropulsion SymmetryTime frame: Baseline.
  • EditedForward PropulsionPropulsion SymmetryTime frame: Immediately after maximal effort exercise test.
Nov 13, 2026
Documents
Secondary outcomes
2 removed
What changed in the outcomes
  • Removedother outcomeInternational Physical Activities QuestionnaireTime frame: Baseline.
  • Removedother outcomeNumber of Participants with Rs6265Time frame: Baseline.
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Results posted
    Primary outcomes 5 edited
    What changed in the outcomes
    • EditedDuration of high intensity exerciseHigh Intensity ExerciseTime frame: From the beginning to the end of the test, as determined based on standardized test termination criteria (e.g., volitional fatigue, cardiovascular abnormalities, or physical safety)
    • EditedConcentration of brainBrain-derived neurotrophic factorNeurotrophic Factor (BDNF)Time frame: Baseline.
    • EditedConcentration of brainBrain-derived neurotrophic factorNeurotrophic Factor (BDNF)Time frame: Immediately after maximal effort exercise test.
    • EditedForward PropulsionPropulsion SymmetryTime frame: Baseline.
    • EditedForward PropulsionPropulsion SymmetryTime frame: Immediately after maximal effort exercise test.
    Secondary outcomes 2 removed
    What changed in the outcomes
    • Removedother outcomeInternational Physical Activities QuestionnaireTime frame: Baseline.
    • Removedother outcomeNumber of Participants with Rs6265Time frame: Baseline.
    Interventions Arms added: Exosuit assistance first, then no exosuit·No exosuit, then exosuit assistance; arms removed: Exercise testing with soft exosuit assistance·Exercise testing without soft exosuit assistance
    + 3 other changes: verification date, responsible party and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05138016
Collaborators
American Heart Association, Harvard University, Spaulding Rehabilitation Hospital
Responsible party
Lou Awad, PT, DPT, PhD (Study Principal Investigator, Boston University Charles River Campus) — Principal investigator
First posted
Nov 30, 2021
Start date
Jul 21, 2021
Primary completion
Aug 28, 2022
Completion
Jan 17, 2023
Results posted
Nov 13, 2026
Last update
Nov 13, 2026

Study contacts

Anna Roto, MS, MPH
study director · Boston University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion